



ASX Announcement

22 February 2023

Change of Company Secretary

Atomo Diagnostics Limited (ASX: AT1) (**Atomo** or the **Company**) wishes to advise in accordance with ASX Listing Rule 3.16.1 that Ms Maria Clemente of BoardRoom Pty Limited has been appointed Company Secretary, with effect from 1 March 2023. For the purposes of ASX Listing Rule 12.6, Ms Clemente will also be the primary person responsible for communications between the Company and the ASX.

Mr Tharun Kupppanda of BoardRoom Pty Limited has notified the Board of his resignation as Company Secretary with effect from 1 March 2023. Atomo thanks Mr Kupppanda for his support of the Board during his time with the Company.

For more information:

John Kelly

MD & CEO, Atomo Diagnostics Limited

john.kelly@atomodiagnostics.com

+61 401 922 279

This announcement was authorised by the Board of Atomo Diagnostics Limited.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com